Regenxbio Inc (RGNX) - Total Liabilities
Based on the latest financial reports, Regenxbio Inc (RGNX) has total liabilities worth $314.85 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Regenxbio Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Regenxbio Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Regenxbio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see RGNX total asset value.
Regenxbio Inc Competitors by Total Liabilities
The table below lists competitors of Regenxbio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Miquel y Costas & Miquel S.A.
MC:MCM
|
Spain | €123.54 Million |
|
Danske Andelskassers Bank A/S
CO:DAB
|
Denmark | Dkr15.45 Billion |
|
Guangdong Shirongzhaoye Co Ltd
SHE:002016
|
China | CN¥2.75 Billion |
|
Qualitas Ltd
AU:QAL
|
Australia | AU$88.55 Million |
|
National Petroleum Co Ltd
TW:9937
|
Taiwan | NT$7.41 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $16.16 Million |
|
GEOPARK LTD. DL -001
F:G6O
|
Germany | €794.65 Million |
|
Brilliance Technology Co Ltd
SHE:300542
|
China | CN¥772.08 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Regenxbio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Regenxbio Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regenxbio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regenxbio Inc (2013–2025)
The table below shows the annual total liabilities of Regenxbio Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $350.30 Million | +69.77% |
| 2024-12-31 | $206.34 Million | -21.31% |
| 2023-12-31 | $262.23 Million | -17.30% |
| 2022-12-31 | $317.07 Million | -9.31% |
| 2021-12-31 | $349.61 Million | +5.81% |
| 2020-12-31 | $330.41 Million | +592.53% |
| 2019-12-31 | $47.71 Million | +36.45% |
| 2018-12-31 | $34.97 Million | +123.45% |
| 2017-12-31 | $15.65 Million | +42.32% |
| 2016-12-31 | $10.99 Million | +140.49% |
| 2015-12-31 | $4.57 Million | -50.24% |
| 2014-12-31 | $9.19 Million | +97.49% |
| 2013-12-31 | $4.65 Million | -- |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more